Cardiovascular problems on hemodialysis: Current deficits and potential improvement

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue SUPPL. 1, 2009, Pages

  Ritz, Eberhard ^a   Bommer, Jü Rgen ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Dialysezentrum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIURETIC AGENT; HORMONE ANTAGONIST; IRBESARTAN; MELATONIN ANTAGONIST; NEBIVOLOL; PHOSPHATE; SPIRONOLACTONE; UNCLASSIFIED DRUG; VITAMIN D;

CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DEPRESSION; DRUG EFFICACY; HEART ARREST; HEART INFARCTION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; INSOMNIA; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MORTALITY; NONHUMAN; RISK FACTOR; SLEEP APNEA SYNDROME; SODIUM RESTRICTION; STROKE; SYMPATHETIC TONE;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY FAILURE, CHRONIC; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 73849123916     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01960309     Document Type: Conference Paper

References (99)

1. Goodkin DA, Young EW, Kurokawa K, Prü tz KG, Levin NW: Mortality among hemodialysis patients in Europe, Japan, and the United States: Case-mix effects. Am J Kidney Dis 44: 16-21, 2004
2. St Peter WL, Liu J, Weinhandl ED, Fan Q: Linking Centers for Medicare & Medicaid Services data with prospective DCOR trial data: Methods and data comparison results. Hemodial Int 12: 480-491, 2008
3. Rayner HC, Pisoni RL, Bommer J, Canaud B, Hecking E, Locatelli F, Piera L, Bragg-Gresham JL, Feldman HI, Goodkin DA, Gillespie B, Wolfe RA, Held PJ, Port FK: Mortality and hospitalization in haemodialysis patients in five European countries: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19: 108-120, 2004
4. Saran R, Bragg-Gresham JL, Levin NW, Twardowski ZJ, Wizemann V, Saito A, Kimata N, Gillespie BW, Combe C, Bommer J, Akiba T, Mapes DL, Young EW, Port FK: Longer treatment time and slower ultrafiltration in hemodialysis: Associations with reduced mortality in the DOPPS. Kidney Int 69: 1222-1228, 2006
5. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E, German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005
6. Remppis A, Ritz E: Cardiac problems in the dialysis patient: Beyond coronary disease. Semin Dial 21: 319-325, 2008
7. Herzog CA, Mangrum JM, Passman R: Sudden cardiac death and dialysis patients. Semin Dial 21: 300-307, 2008
8. Herzog CA. Cardiac arrest in dialysis patients: Approaches to alter an abysmal outcome. Kidney Int Suppl (84): S197-S200, 2003
9. Myerburg RJ, Castellanos A: Emerging paradigms of the epidemiology and demographics of sudden cardiac arrest. Heart Rhythm 3: 235-239, 2006
10. Piecha G, Koleganova N, Gross ML, Geldyyev A, Ritz E: Oxidative stress after uninephrectomy alters heart morphology in the apolipoprotein E -/- mouse. J Hypertens 26: 2220-2229, 2008
11. Gross ML, Ritz E: Hypertrophy and fibrosis in the cardiomyopathy of uremia: Beyond coronary heart disease. Semin Dial 21: 308-318, 2008
12. Mark PB, Johnston N, Groenning BA, Foster JE, Blyth KG, Martin TN, Steedman T, Dargie HJ, Jardine AG: Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 69: 1839-1845, 2006
13. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE: Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 11: 1277-1285, 1996
14. Siedlecki AM, Jin X, Muslin AJ: Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int 75: 800-808, 2009
15. Ritz E: Left ventricular hypertrophy in renal disease: Beyond preload and afterload. Kidney Int 75: 771-773, 2009
16. Charra B, Calemard E, Ruffet M, Chazot C, Terrat JC, Vanel T, Laurent G: Survival as an index of adequacy of dialysis. Kidney Int 41: 1286-1291, 1992
17. Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, Van Stone J, Levey A, Meyer KB, Klag MJ, Johnson HK, Clark E, Sadler JH, Teredesai P: "U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. [published erratum appears in Kidney Int 54: 1417, 1998]. Kidney Int 54: 561-569, 1998
18. Scribner BH, Buri R, Caner JE, Hegstrom R, Burnell JM: The treatment of chronic uremia by means of intermittent hemodialysis: A preliminary report. Trans Am Soc Artif Intern Organs 6: 114-122, 1960
19. Bragg-Gresham JL, Fissell RB, Mason NA, Bailie GR, Gillespie BW, Wizemann V, Cruz JM, Akiba T, Kurokawa K, Ramirez S, Young EW: Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney Dis 49: 426-431, 2007
20. Elliott P, Walker LL, Little MP, Blair-West JR, Shade RE, Lee DR, Rouquet P, Leroy E, Jeunemaitre X, Ardaillou R, Paillard F, Meneton P, Denton DA: Change in salt intake affects blood pressure of chimpanzees: Implications for human populations [published erratum appears in Circulation 116: e370, 2007]. Circulation 116: 1563-1568, 2007
21. Fava C, Montagnana M, Rosberg L, Burri P, Almgren P, Jönsson A, Wanby P, Lippi G, Minuz P, Hulthèn LU, Aurell M, Melander O: Subjects heterozygous for genetic loss of function of the thiazide-sensitive cotransporter have reduced blood pressure. Hum Mol Genet 17: 413-418, 2008
22. Frohlich ED: The salt conundrum: A hypothesis. Hypertension 50: 161-166, 2007
23. Matavelli LC, Zhou X, Varagic J, Susic D, Frohlich ED: Salt loading produces severe renal hemodynamic dysfunction independent of arterial pressure in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 292: H814-H819, 2007
24. Ahmad S, Kenny M, Scribner BH: Hypertension and a digoxin-like substance in the plasma of dialysis patients: Possible marker for a natriuretic hormone. Clin Physiol Biochem 4: 210-216, 1986
25. Schoner W, Scheiner-Bobis G: Role of endogenous cardiotonic steroids in sodium homeostasis. Nephrol Dial Transplant 23: 2723-2729, 2008
26. Kennedy DJ, Vetteth S, Periyasamy SM, Kanj M, Fedorova L, Khouri S, Kahaleh MB, Xie Z, Malhotra D, Kolodkin NI, Lakatta EG, Fedorova OV, Bagrov AY, Shapiro JI: Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension 47: 488-495, 2006
27. Fedorova LV, Raju V, El-Okdi N, Shidyak A, Kennedy DJ, Vetteth S, Giovannucci DR, Bagrov AY, Fedorova OV, Shapiro JI, Malhotra D: The cardiotonic steroid hormone marinobufagenin induces renal fibrosis: Implication of epithelial-to-mesenchymal transition. Am J Physiol Renal Physiol 296: F922-F934, 2009
28. Stella P, Manunta P, Mallamaci F, Melandri M, Spotti D, Tripepi G, Hamlyn JM, Malatino LS, Bianchi G, Zoccali C: Endogenous ouabain and cardiomyopathy in dialysis patients. J Intern Med 263: 274-280, 2008
29. Ferrari P, Ferrandi M, Valentini G, Bianchi G: Rostafuroxin: An ouabain antagonist that corrects renal and vascular Na+-K+-ATPase alterations in ouabain and adducin-dependent hypertension. Am J Physiol Regul Integr Comp Physiol 290: R529-R535, 2006
30. Huang BS, Amin MS, Leenen FH: The central role of the brain in salt-sensitive hypertension. Curr Opin Cardiol 21: 295-304, 2006
31. Oberleithner H, Callies C, Kusche-Vihrog K, Schillers H, Shahin V, Riethmü ller C, Macgregor GA, de Wardener HE: Potassium softens vascular endothelium and increases nitric oxide release. Proc Natl Acad Sci U S A 106: 2829-2834, 2009
32. Ritz E, Dikow R, Morath C, Schwenger V: Salt: A potential 'uremic toxin'? Blood Purif 24: 63-66, 2006
33. de Wardener HE, He FJ, MacGregor GA: Plasma sodium and hypertension. Kidney Int 66: 2454-2466, 2004
34. Huang BS, Ahmad M, Deng AY, Leenen FH: Neuronal responsiveness to central Na+ in 2 congenic strains of Dahl salt-sensitive rats. Hypertension 49: 1315-1320, 2007
35. London GM: Brachial arterial pressure to assess cardiovascular structural damage: An overview and lessons from clinical trials. J Nephrol 21: 23-31, 2008
36. Gross E, Rothstein M, Dombek S, Juknis HI: Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis 46: 94-101, 2005
37. Saudan P, Mach F, Perneger T, Schnetzler B, Stoermann C, Fumeaux Z, Rossier M, Martin PY: Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol Dial Transplant 18: 2359-2363, 2003
38. Hussain S, Dreyfus DE, Marcus RJ, Biederman RW, McGill RL: Is spironolactone safe for dialysis patients? Nephrol Dial Transplant 18: 2364-2368, 2003
39. Oberleithner H, Riethmü ller C, Schillers H, MacGregor GA, de Wardener HE, Hausberg M: Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc Natl Acad Sci U S A 104: 16281-16286, 2007
40. Brilla CG, Maisch B, Zhou G, Weber KT: Hormonal regulation of cardiac fibroblast function. Eur Heart J 16[Suppl C]: 45-50, 1995
41. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ: Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 12: 2427-2433, 2001
42. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327: 1912-1918, 1992
43. Ye S, Ozgur B, Campese VM: Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 51: 722-727, 1997
44. Vonend O, Oberhauser V, von Kü gelgen I, Apel TW, Amann K, Ritz E, Rump LC: ATP release in human kidney cortex and its mitogenic effects in visceral glomerular epithelial cells. Kidney Int 61: 1617-1626, 2002
45. Bakris GL, Hart P, Ritz E: Beta blockers in the management of chronic kidney disease. Kidney Int 70: 1905-1913, 2006
46. Hamar P, Kokeny G, Liptak P, Krtil J, Adamczak M, Amann K, Ritz E, Gross ML: The combination of ACE inhibition plus sympathetic denervation is superior to ACE inhibitor monotherapy in the rat renal ablation model. Nephron Exp Nephrol 105: e124-e136, 2007
47. Amann K, Hofstetter J, Câmpean V, Koch A, Gross ML, Veelken R, Ritz E: Nonhypotensive dose of beta-adrenergic blocker ameliorates capillary deficits in the hearts of rats with moderate renal failure. Virchows Arch 449: 207-214, 2006
48. Flierl MA, Rittirsch D, Chen AJ, Sarma JV, Zetoune FS, McGuire SR, List RP, Day DE, Hoesel LM, Gao H, Van Rooijen N, Huber-Lang MS, Neubig RR, Ward PA: Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature 449: 721-725, 2007
49. Flierl MA, Rittirsch D, Nadeau BA, Sarma JV, Day DE, Lentsch AB, Huber-Lang MS, Ward PA: Upregulation of phagocyte-derived catecholamines augments the acute inflammatory response. PLoS ONE 4: e4414, 2009
50. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: 1524-1538, 2002
51. Li G, Xu J, Wang P, Velazquez H, Li Y, Wu Y, Desir GV: Catecholamines regulate the activity, secretion, and synthesis of renalase. Circulation 117: 1277-1282, 2008
52. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819-823, 1984
53. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS: Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105: 1354-1359, 2002
54. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998
55. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520-528, 2005
56. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G, Cholesterol And Recurrent Events Trial Investigators: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112: 2627-2633, 2005
57. Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA, Thadhani R, Kang PM: Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A 104: 16810-16815, 2007
58. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jü ppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592, 2008
59. Merke J, Milde P, Lewicka S, Hü gel U, Klaus G, Mangelsdorf DJ, Haussler MR, Rauterberg EW, Ritz E: Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3: Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest 83: 1903-1915, 1989
60. Li YC, Kong J, Wei M, Liu SQ, Cao LP: 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the reninangiotensin system. J Clin Invest 110: 229-238, 2002
61. Kimmel PL, Miller G, Mendelson WB: Sleep apnea syndrome in chronic renal disease. Am J Med 86: 308-314, 1989
62. Pressman MR, Benz RL, Schleifer CR, Peterson DD: Sleep disordered breathing in ESRD: Acute beneficial effects of treatment with nasal continuous positive airway pressure. Kidney Int 43: 1134-1139, 1993
63. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S: The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328: 1230-1235, 1993
64. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V: Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 353: 2034-2041, 2005
65. Zoccali C, Mallamaci F, Tripepi G: Nocturnal hypoxemia predicts incident cardiovascular complications in dialysis patients. J Am Soc Nephrol 13: 729-733, 2002
66. Bradley TD, Floras JS: Obstructive sleep apnoea and its cardiovascular consequences. Lancet 373: 82-93, 2009
67. Hanly PJ, Pierratos A: Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 344: 102-107, 2001
68. Lopes AA, Bragg J, Young E, Goodkin D, Mapes D, Combe C, Piera L, Held P, Gillespie B, Port FK, Dialysis Outcomes and Practice Patterns Study (DOPPS): Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney Int 62: 199-207, 2002
69. Ferketich AK, Schwartzbaum JA, Frid DJ, Moeschberger ML: Depression as an antecedent to heart disease among women and men in the NHANES I study. National Health and Nutrition Examination Survey. Arch Intern Med 160: 1261-1268, 2000
70. Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA, Blackett KN, Sitthi-amorn C, Sato H, Yusuf S, INTERHEART investigators: Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): Case-control study. Lancet 364: 953-962, 2004
71. Glassman AH, Shapiro PA: Depression and the course of coronary artery disease. Am J Psychiatry 155: 4-11, 1998
72. Everson-Rose SA, Meyer PM, Powell LH, Pandey D, Torréns JI, Kravitz HM, Bromberger JT, Matthews KA: Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife. Diabetes Care 27: 2856-2862, 2004
73. Miller AH, Maletic V, Raison CL: Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65: 732-741, 2009
74. Capuron L, Su S, Miller AH, Goldberg J, Vogt GJ, Maisano C, Jones L, Murrah NV, Vaccarino V: Depressive symptoms and metabolic syndrome: Is inflammation the underlying link? Biol Psychiatry 64: 896-900, 2008
75. Raison CL, Capuron L, Miller AH: Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol 27: 24-31, 2006
76. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R: Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial. Lancet 367: 29-35, 2006
77. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB, Miller AH: Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344: 961-966, 2001
78. Finkelstein FO, West W, Gobin J, Finkelstein SH, Wuerth D: Spirituality, quality of life and the dialysis patient. Nephrol Dial Transplant 22: 2432-2434, 2007
79. Tong A, Sainsbury P, Craig JC: Support interventions for caregivers of people with chronic kidney disease: A systematic review. Nephrol Dial Transplant 23: 3960-3965, 2008
80. Somers VK: Sleep: A new cardiovascular frontier. N Engl J Med 353: 2070-2073, 2005
81. Merlino G, Piani A, Dolso P, Adorati M, Cancelli I, Valente M, Gigli GL: Sleep disorders in patients with end-stage renal disease undergoing dialysis therapy. Nephrol Dial Transplant 21: 184-190, 2006
82. Muller JE, Tofler GH, Stone PH: Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 79: 733-743, 1989
83. Eastman CI, Boulos Z, Terman M, Campbell SS, Dijk DJ, Lewy AJ: Light treatment for sleep disorders: consensus report: VI. Shift work. J Biol Rhythms 10: 157-164, 1995
84. Martino TA, Oudit GY, Herzenberg AM, Tata N, Koletar MM, Kabir GM, Belsham DD, Backx PH, Ralph MR, Sole MJ: Circadian rhythm disorganization produces profound cardiovascular and renal disease in hamsters [published erratum appears in Am J Physiol Regul Integr Comp Physiol 295: R369, 2008]. Am J Physiol Regul Integr Comp Physiol 294: R1675-R1683, 2008
85. Elder SJ, Pisoni RL, Akizawa T, Fissell R, Andreucci VE, Fukuhara S, Kurokawa K, Rayner HC, Furniss AL, Port FK, Saran R: Sleep quality predicts quality of life and mortality risk in haemodialysis patients: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 23: 998-1004, 2008
86. Rajaratnam SM, Polymeropoulos MH, Fisher DM, Roth T, Scott C, Birznieks G, Klerman EB: Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleeptime shift: Two randomised controlled multicentre trials [published erratum appears in Lancet 373: 1252, 2009]. Lancet 373: 482-491, 2009
87. Scribner BH: Lasker Clinical Medicine Research Award. Medical dilemmas: The old is new. Nat Med 8: 1066-1067, 2002
88. Strippoli GF, Craig JC, Schena FP: The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol 15: 411-419, 2004
89. van Rooij E, Marshall WS, Olson EN: Toward microRNA-based therapeutics for heart disease: The sense in antisense. Circ Res 103: 919-928, 2008
90. Himmelfarb J: Oxidative stress in hemodialysis. Contrib Nephrol 161: 132-137, 2008
91. Mann JF, Sheridan P, McQueen MJ, Held C, Arnold JM, Fodor G, Yusuf S, Lonn EM, HOPE-2 investigators: Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease: Results of the renal Hope-2 study. Nephrol Dial Transplant 23: 645-653, 2008
92. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM, Veterans Affairs Site Investigators: Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: A randomized controlled trial [published erratum appears in JAMA 300: 170 2008]. JAMA 298: 1163-1170, 2007
93. Bostom AG, Carpenter MA, Hunsicker L, Jacques PF, Kusek JW, Levey AS, McKenney JL, Mercier RY, Pfeffer MA, Selhub J, FAVORIT Study Investigators: Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. Am J Kidney Dis 53: 121-128, 2009
94. Port FK, Hulbert-Shearon TE, Wolfe RA, Bloembergen WE, Golper TA, Agodoa LY, Young EW: Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 33: 507-517, 1999
95. Heerspink HJ, Ninomiya T, Zoungas S, de Zeeuw D, Grobbee DE, Jardine MJ, Gallagher M, Roberts MA, Cass A, Neal B, Perkovic V: Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: A systematic review and meta-analysis of randomised controlled trials. Lancet 373: 1009-1015, 2009
96. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ: Dogma disputed: Can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 144: 884-893, 2006
97. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Pohl M, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ, Collaborative Study Group: Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 16: 2170-2179, 2005
98. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group: Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
99. Wang JG, Li Y, Franklin SS, Safar M: Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: A quantitative overview. Hypertension 50: 181-188, 2007